Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Konverze nemocných z léčby kalcineurinovými inhibitory na sirolimus
[Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial]

Schena FP, Pascoe MD, Alberu J, Carmen Rial del M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Dolinsky M, Goldber-Albers R, LI H, Scarola J, Neylan JF, for the Sirolimus CONVERT Trial Study Group.

. 2009 ; 7 (2) : 30-31.

Language Czech Country Czech Republic

Persistent link   https://www.medvik.cz/link/bmc07526600

The efficacy and safety of converting maintenance renal transplant recipients from calcineurin inhibitors (CNIs) to sirolimus (SRL) was evaluated. METHODS: Eight hundred thirty renal allograft recipients, 6 to 120 months posttransplant and receiving cyclosporine or tacrolimus, were randomly assigned to continue CNI (n=275) or convert from CNI to SRL (n=555). Primary endpoints were calculated Nankivell glomerular filtration rate (GFR; stratified at baseline: 20-40 vs. >40 mL/min) and the cumulative rates of biopsy-confirmed acute rejection (BCAR), graft loss, or death at 12 months. Enrollment in the 20 to 40 mL/min stratum was halted prematurely because of a higher incidence of safety endpoints in the SRL conversion arm. RESULTS: Intent-to-treat analyses at 12 and 24 months showed no significant treatment difference in GFR in the baseline GFR more than 40 mL/min stratum. On-therapy analysis of this cohort showed significantly higher GFR at 12 and 24 months after SRL conversion. Rates of BCAR, graft survival, and patient survival were similar between groups. Median urinary protein-to-creatinine ratios (UPr/Cr) were similar at baseline but increased significantly after SRL conversion. Malignancy rates were significantly lower at 12 and 24 months after SRL conversion. Post hoc analyses identified a subgroup with baseline GFR more than 40 mL/min and UPr/Cr less than or equal to 0.11, whose risk-benefit profile was more favorable after conversion than that for the overall SRL conversion cohort. CONCLUSIONS: At 2 years, SRL conversion among patients with baseline GFR more than 40 mL/min was associated with excellent patient and graft survival, no difference in BCAR, increased urinary protein excretion, and a lower incidence of malignancy compared with CNI continuation. Superior renal function was observed among patients who remained on SRL through 12 to 24 months, particularly in the subgroup of patients with baseline GFR more than 40 mL/min and UPr/Cr less than or equal to 0.11.

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

Recenze v:

Komentář [k článku Konverze nemocných z léčby kalcineurinovými inhibitory na sirolimus].

000      
00000naa 2200000 a 4500
001      
bmc07526600
003      
CZ-PrNML
005      
20111210143339.0
008      
090728s2009 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Schena, F. P.
245    10
$a Konverze nemocných z léčby kalcineurinovými inhibitory na sirolimus / $c Schena FP, Pascoe MD, Alberu J, Carmen Rial del M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Dolinsky M, Goldber-Albers R, LI H, Scarola J, Neylan JF, for the Sirolimus CONVERT Trial Study Group.
246    11
$a Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial
314    __
$a Renal, Dialysis and Transplant Unit, Department of Emergency and Organ Transplant, University of Bari, Bari fp.schena@nephro.uniba.it
520    9_
$a The efficacy and safety of converting maintenance renal transplant recipients from calcineurin inhibitors (CNIs) to sirolimus (SRL) was evaluated. METHODS: Eight hundred thirty renal allograft recipients, 6 to 120 months posttransplant and receiving cyclosporine or tacrolimus, were randomly assigned to continue CNI (n=275) or convert from CNI to SRL (n=555). Primary endpoints were calculated Nankivell glomerular filtration rate (GFR; stratified at baseline: 20-40 vs. >40 mL/min) and the cumulative rates of biopsy-confirmed acute rejection (BCAR), graft loss, or death at 12 months. Enrollment in the 20 to 40 mL/min stratum was halted prematurely because of a higher incidence of safety endpoints in the SRL conversion arm. RESULTS: Intent-to-treat analyses at 12 and 24 months showed no significant treatment difference in GFR in the baseline GFR more than 40 mL/min stratum. On-therapy analysis of this cohort showed significantly higher GFR at 12 and 24 months after SRL conversion. Rates of BCAR, graft survival, and patient survival were similar between groups. Median urinary protein-to-creatinine ratios (UPr/Cr) were similar at baseline but increased significantly after SRL conversion. Malignancy rates were significantly lower at 12 and 24 months after SRL conversion. Post hoc analyses identified a subgroup with baseline GFR more than 40 mL/min and UPr/Cr less than or equal to 0.11, whose risk-benefit profile was more favorable after conversion than that for the overall SRL conversion cohort. CONCLUSIONS: At 2 years, SRL conversion among patients with baseline GFR more than 40 mL/min was associated with excellent patient and graft survival, no difference in BCAR, increased urinary protein excretion, and a lower incidence of malignancy compared with CNI continuation. Superior renal function was observed among patients who remained on SRL through 12 to 24 months, particularly in the subgroup of patients with baseline GFR more than 40 mL/min and UPr/Cr less than or equal to 0.11.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a biopsie $7 D001706
650    _2
$a kalcineurin $7 D019703
650    _2
$a cyklosporin $x aplikace a dávkování $x škodlivé účinky $7 D016572
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hodnoty glomerulární filtrace $x účinky léků $7 D005919
650    _2
$a rejekce štěpu $7 D006084
650    _2
$a přežívání štěpu $x účinky záření $7 D006085
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x aplikace a dávkování $x škodlivé účinky $7 D007166
650    _2
$a transplantace ledvin $x mortalita $x škodlivé účinky $7 D016030
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory $x etiologie $x prevence a kontrola $7 D009369
650    _2
$a prospektivní studie $7 D011446
650    _2
$a sirolimus $x aplikace a dávkování $x škodlivé účinky $7 D020123
650    _2
$a takrolimus $x aplikace a dávkování $x škodlivé účinky $7 D016559
650    _2
$a časové faktory $7 D013997
650    _2
$a homologní transplantace $7 D014184
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
650    _2
$a inhibitory kalcineurinu $7 D065095
700    1_
$a Pascoe, M. D.
700    1_
$a Alberu, Josefina $7 gn_A_00003508
700    1_
$a Carmen Rial, Maria del
700    1_
$a Oberbauer, R.
700    1_
$a Brennan, D. C.
700    1_
$a Campistol, J. M.
700    1_
$a Racusen, L.
700    1_
$a Dolinsky, M.
700    1_
$a Goldber-Albers, R.
700    1_
$a Li, H.
700    1_
$a Scarola, J.
700    1_
$a Neylan, J. F.
773    0_
$w MED00012709 $t Postgraduální nefrologie $g Roč. 7, č. 2 (2009), s. 30-31 $x 1214-178X
787    18
$w bmc07526601 $i Recenze v: $t Komentář [k článku Konverze nemocných z léčby kalcineurinovými inhibitory na sirolimus]
856    41
$u http://www.transplant.cz/vzdelavani/2009/09_02_11.pdf $y plný text volně přístupný
910    __
$a ABA008 $b B 2318 $c 893 $y 9
990    __
$a 20090724142639 $b ABA008
991    __
$a 20090907120825 $b ABA008
999    __
$a ok $b bmc $g 670239 $s 529004
BAS    __
$a 3
BMC    __
$a 2009 $b 7 $c 2 $d 30-31 $i 1214-178X $m Postgraduální nefrologie $x MED00012709
LZP    __
$a 2009-25/mkme

Find record

Citation metrics

Archiving options